CO-DIAGNOSTICS INC (CODX:NASDAQ)
$1.12 0.02 (1.8182%)
Analysed CO-DIAGNOSTICS INC (CODX:NASDAQ) News Sources
Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test
01-07-2026
yahoo.com
Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand
08-07-2026
yahoo.com
Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer
16-07-2026
yahoo.com
EXCLUSIVE: Co-Diagnostics Announces Successful Proof of Concept for Extraction-Free Ebola Test
28-07-2026
yahoo.com
Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast
30-07-2026
yahoo.com
Co-Diagnostics Reports Second Quarter 2026 Financial Results
13-08-2026
yahoo.com
Co-Diagnostics Inc (CODX) (Q2 2026) Earnings Call Highlights: FDA Submission Milestone and ...
14-08-2026
yahoo.com
Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event
18-08-2026
yahoo.com
Co-Dx (CODX) Q2 2026 Earnings Call Transcript
20-08-2026
fool.com
Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
01-09-2026
yahoo.com
What is the current price of CO-DIAGNOSTICS INC (CODX:NASDAQ)?
The current price of CO-DIAGNOSTICS INC (CODX:NASDAQ) is $1.12.
CO-DIAGNOSTICS INC (CODX:NASDAQ) absolute price change since previous trading day?
The absolute price change of CO-DIAGNOSTICS INC (CODX:NASDAQ) since the previous trading day is $0.02.
CO-DIAGNOSTICS INC (CODX:NASDAQ) percentage price change since previous trading day?
The percentage price change of CO-DIAGNOSTICS INC (CODX:NASDAQ) since the previous trading day is 1.8182%.
What is the most recent average sentiment score for CO-DIAGNOSTICS INC (CODX:NASDAQ)?
The most recent average sentiment score for CO-DIAGNOSTICS INC (CODX:NASDAQ) is 60 out of 100.
What is the most recent average sentiment for CO-DIAGNOSTICS INC (CODX:NASDAQ)?
The most recent sentiment for CO-DIAGNOSTICS INC (CODX:NASDAQ) is .
SEC-8K** Filing Available For CO-DIAGNOSTICS INC (CODX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.